Advertisements



Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting

Analysts at Cantor Fitzgerald continue to hold a bullish stance on Spark Therapeutics Inc (NASDAQ: ONCE) after the U.S. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

All The Sell-Side Responses To Spark Therapeutics" Strong AdCom Meeting On Luxturna

On Thursday afternoon, and FDA advisory panel recommended approval of Spark Therapeutics Inc (NASDAQ: ONCE)’s Luxturna treatment for inherited blindness. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting

Biotech stocks were active Monday as analysts weighed in on a raft of announcements from companies attending the American Society of Hematology annual meeting......»»

Category: topSource: marketwatch7 hr. 47 min. ago

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote.....»»

Category: topSource: seekingalphaOct 17th, 2017

Credit Suisse Weighs In Ahead Of PTC Therapeutics" Thursday AdCom Panel For Translarna

PTC Therapeutics, Inc. (NASDAQ: PTCT) is already experiencing some major volatility Tuesday ahead of its upcoming AdCom meeting for Duchenne muscular dystrophy drug candidate Translarna on Thursday. Latest Ratings for PTCT DateFir.....»»

Category: blogSource: benzingaSep 26th, 2017

Spark Therapeutics announces multiple presentations at ASH Annual Meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active trader.....»»

Category: blogSource: theflyonthewallNov 30th, 2016

Goldcorp, Spark Therapeutics Tumble into Monday’s 52-Week Low Club

Spark Therapeutics, Goldcorp, Sprint, and Syros Pharmaceuticals all posted new 52-week lows Monday......»»

Category: blogSource: 247wallst3 hr. 2 min. ago

Spark Therapeutics" (ONCE) Special Call Broker Conference Call (Transcript)

Spark Therapeutics" (ONCE) Special Call Broker Conference Call (Transcript).....»»

Category: topSource: seekingalpha3 hr. 17 min. ago

Apple and Chesapeake Energy rise; Spark Therapeutics sinks

Stocks that moved substantially or traded heavily Monday: Bluebird Bio Inc., up $30.65 to $201.80 Bluebird and Celgene reported positive results from an early clinical trial of a multiple myeloma treatment......»»

Category: topSource: foxnews3 hr. 17 min. ago

Analyst: Weakness In Spark Therapeutics Is Overdone

Spark Therapeutics Inc (NASDAQ: ONCE) reported during the ASH conference an update concerning its SPK-8011 therapy, which has many investors concerned. Latest R.....»»

Category: blogSource: benzinga5 hr. 47 min. ago

CRISPR Therapeutics (CRSP) Presents At 59th American Society Of Hematology Annual Meeting - Slideshow

CRISPR Therapeutics (CRSP) Presents At 59th American Society Of Hematology Annual Meeting - Slideshow.....»»

Category: topSource: seekingalpha6 hr. 32 min. ago

Here"s Why Spark Therapeutics, Inc. Is Getting Hammered Today

The latest data for a candidate partnered with Pfizer bodes well for a potential competitor......»»

Category: topSource: foxnews6 hr. 32 min. ago

Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive than a rival product from BioMarin Pharma.....»»

Category: topSource: marketwatch8 hr. 47 min. ago

Why Spark Therapeutics stock price dropped by 40% this morning

Spark Therapeutics’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment. Preliminary clinical data showed the gene therapy treat.....»»

Category: topSource: bizjournals9 hr. 2 min. ago

Lighting a Spark for Gene Therapy

A treatment for hemophilia B being developed by Spark Therapeutics and Pfizer gets highlighted in The New England Journal of Medicine......»»

Category: topSource: barronsDec 8th, 2017

UM Ventures launches new fund, entrepreneurship space in Lion Brothers building

A new innovation space from the University of Maryland, Baltimore is opening inside the historic Lion Brothers building on Hollins Street. About 6,200 square feet of the 38,000-square-foot building will be dedicated to offices, class/meeting rooms.....»»

Category: topSource: bizjournalsDec 7th, 2017

Gene-therapy approach to hemophilia finds success in study, Spark stock surges

Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration with Pfizer Inc. , involves a sin.....»»

Category: topSource: marketwatchDec 6th, 2017

Inside the "treacherous shenanigans" of 93-year-old Robert Mugabe"s downfall as Zimbabwe"s sole leader for 37 years

Thomson Reuters President Robert Mugabe, with Zimbabwe's supreme law on his side, faced off against the military, his party, and Zimbabwe's people in a dramatic five-day standof.....»»

Category: topSource: businessinsiderNov 26th, 2017

Amsterdam, Paris win post-Brexit EU agencies

Amsterdam and Paris won the right to host the two EU agencies that must leave London on Brexit after a dramatic ministerial meeting in Brussels that left both results decided by drawing lots after votes were tied. David Doyle reports.....»»

Category: videoSource: reutersNov 20th, 2017

Amsterdam, Paris win post-Brexit EU agencies in lucky dip thrillers

BRUSSELS (Reuters) - Amsterdam and Paris won the right to host the two EU agencies that must leave London on Brexit after a dramatic ministerial meeting in Brussels that left both result decided by drawing lots after votes were tied......»»

Category: topSource: reutersNov 20th, 2017

Aileron Therapeutics Reports Third Quarter 2017 Financial Results

Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS Two abstracts selected for oral presentations at American Society of Hematology Annual Meeting, highlighting potentia.....»»

Category: earningsSource: benzingaNov 9th, 2017